Sign up to save your podcasts
Or
Share AI Access Brief Podcast
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AI Access Brief Podcast
AI Access Brief Podcast episodes
- HCA Warning & Leqembi ShiftEpisode 143 — 19 October 2026HCA's profit warning signals US access erosion; subcutaneous Leqembi reshapes Alzheimer's value; FTC-CVS settlement exposes PBM practices; ICER expands early-phase HEOR support.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
- HCA Warning, Leqembi, FTC, ICEREpisode 142 — 18 October 2026HCA profit warning signals US access erosion; subcutaneous Leqembi, FTC insulin settlement, and ICER scientific advice reshape market access strategies.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- US Access Erosion SignalsEpisode 141 — 17 October 2026Analyzing HCA's profit warning as a symptom of US access erosion, subcutaneous Leqembi's impact on Alzheimer's value narratives, FTC-CVS insulin settlement implications for PBMs, and ICER's early-phase scientific advice expansion.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- HTA Methodology Shifts & Alzheimer's AccessEpisode 140 — 16 October 2026Examining evolving HTA methodologies, Alzheimer's treatment access challenges, and the operational hurdles of major healthcare system reforms.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast14 min
- HTA Methodology Shifts & AI IntegrationEpisode 139 — 14 October 2026Examining evolving HTA methodologies, adaptive licensing expansions, and decentralized trial guidance with implications for evidence generation.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
- HCA Warning, Leqembi SC, FTC CVS, ICER AdviceEpisode 138 — 13 October 2026HCA's profit warning signals US access erosion; subcutaneous Leqembi reshapes Alzheimer's evidence needs; FTC-CVS settlement exposes PBM practices; ICER expands early-phase advice to de-risk development.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast14 min
- FDA CAR-T Approval & NICE CGT FrameworkEpisode 137 — 12 October 2026Examining FDA's CAR-T breakthrough for solid tumors, NICE's revised CGT value framework, CMS's 2027 Star Ratings shift, and EU's non-oncology JCA rollout.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- Payer Evidence DemandsEpisode 136 — 11 October 2026Examining how payer evidence demands are reshaping HEOR strategies, with focus on RWE integration, value demonstration for complex therapies, and rare disease HTA adaptations.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast17 min
- US Market Access Shifts: Profit Warnings, New Approvals, and Policy ChangesEpisode 135 — 10 October 2026Episode 135 examines critical shifts in US market access, including HCA's profit warning signaling access challenges, subcutaneous Leqembi's impact on Alzheimer's treatment value, the FTC-CVS insulin settlement revealing PBM practices, and ICER's expanded early-phase scientific advice reshaping development strategies.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
- US Access Shifts: Leqembi, PBMs, and Early HEOR StrategyEpisode 134 — 09 October 2026HCA's profit warning signals US healthcare access erosion; Leqembi's subQ approval and FTC-CVS insulin settlement reshape market dynamics, while ICER's early-phase advice expands HEOR evidence strategy.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
About AI Access Brief Podcast
From the publisher's feed
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and…
evidence strategy.